AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 4.1% in the third quarter, Holdings Channel reports. The fund owned 1,702,781 shares of the biotechnology company’s stock after selling 72,916 shares during the period. Vanguard Group Inc. owned 0.06% of AnaptysBio worth $30,582,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of AnaptysBio by 2.1% during the first quarter. BlackRock Inc. now owns 1,895,494 shares of the biotechnology company’s stock worth $41,246,000 after purchasing an additional 39,228 shares during the period. State Street Corp lifted its stake in shares of AnaptysBio by 10.0% in the 3rd quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock worth $32,442,000 after acquiring an additional 115,846 shares during the period. Woodline Partners LP boosted its holdings in shares of AnaptysBio by 125.1% in the second quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock valued at $21,043,000 after acquiring an additional 574,987 shares in the last quarter. Braidwell LP increased its stake in shares of AnaptysBio by 34.0% during the first quarter. Braidwell LP now owns 973,073 shares of the biotechnology company’s stock worth $21,174,000 after acquiring an additional 246,951 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in AnaptysBio by 1.8% during the first quarter. Dimensional Fund Advisors LP now owns 958,660 shares of the biotechnology company’s stock worth $20,860,000 after purchasing an additional 16,528 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ANAB. Piper Sandler assumed coverage on AnaptysBio in a report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, April 1st. Wedbush upgraded AnaptysBio from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. Wells Fargo & Company started coverage on shares of AnaptysBio in a research report on Thursday. They set an “overweight” rating and a $56.00 target price on the stock. Finally, BTIG Research began coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.13.

Insider Transactions at AnaptysBio

In related news, CEO Daniel Faga sold 3,000 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other AnaptysBio news, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares of the company’s stock, valued at approximately $81,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Faga sold 3,000 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The disclosure for this sale can be found here. Insiders sold a total of 157,005 shares of company stock valued at $3,586,199 over the last three months. 35.50% of the stock is currently owned by insiders.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $24.73 on Friday. The firm’s 50-day moving average is $23.56 and its two-hundred day moving average is $20.43. AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $27.50. The company has a market capitalization of $661.85 million, a PE ratio of -4.07 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. On average, analysts forecast that AnaptysBio, Inc. will post -6.25 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.